Exchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology
-2.56% $0.190
/ 17 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 15.81 mill |
EPS: | -6.25 |
P/E: | -0.0300 |
Earnings Date: | Mar 30, 2023 |
SharesOutstanding: | 83.20 mill |
Avg Daily Volume: | 0 mill |
RATING 2024-04-17 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Sell | |
DE: | Strong Sell | |
P/E: | Buy | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | ||
Ebit | ||||||
Asset | ||||||
Debt | n/a | n/a |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.0300 | sector: PE 0 |
PE RATIO: COMPANY / INDUSTRY |
---|
0x |
Company: PE -0.0300 | industry: PE 0 |
DISCOUNTED CASH FLOW VALUE |
---|
$-0.603 (-417.20%) $-0.793 |
Date: 2024-04-18 |
Expected Trading Range (DAY) |
---|
$ 0.168 - 0.212 ( +/- 11.58%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-28 | Rehnquist Janet | Buy | 0 | |
2023-09-13 | Narido Richard Clavano | Buy | 0 | |
2023-08-30 | Gorovitz Aaron | Buy | 35 000 | Common Stock, par value $0.001 per share |
2023-08-30 | Hurvitz Chaim | Buy | 70 000 | Common Stock, par value $0.001 per share |
2023-08-23 | Javitt Jonathan C | Buy | 100 000 | Common Stock |
INSIDER POWER |
---|
58.90 |
Last 31 transactions |
Buy: 2 175 064 | Sell: 638 108 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.190 (-2.56% ) |
Volume | 0.0061 mill |
Avg. Vol. | 0 mill |
% of Avg. Vol | 0 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.